Lentiviral vector-mediated RNAi and its use for cancer research

Future Oncology

Volumn 3, Issue 6, 2007, Pages 655-664

  Sumimoto, Hidetoshi ^a   Kawakami, Yutaka ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cancer; Gene therapy; HIV; Lentiviral vector; RNAi; shRNA

Indexed keywords

ADENOVIRUS VECTOR; ARGININE; CRE RECOMBINASE; DICER; DNA DIRECTED RNA POLYMERASE III; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EXPORTIN 5; IMMUNOGLOBULIN F(AB) FRAGMENT; INTERFERON; LENTIVIRUS VECTOR; NANOPARTICLE; PARVOVIRUS VECTOR; PLASMID VECTOR; PROTAMINE; RETROVIRUS VECTOR; RNA INDUCED SILENCING COMPLEX; SHORT HAIRPIN RNA; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN;

ANTIBODY PRODUCTION; CANCER GENE THERAPY; CANCER RESEARCH; CARCINOGENESIS; CELL DIVISION; CLINICAL FEATURE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DOWN REGULATION; DRUG RESEARCH; EXPRESSION VECTOR; GENE FUNCTION; GENE INACTIVATION; GENETIC ANALYSIS; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; LONG TERMINAL REPEAT; LOXP SITE; MALIGNANT NEOPLASTIC DISEASE; POSTTRANSCRIPTIONAL GENE SILENCING; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN INDUCTION; PSEUDOTYPING; RABIES VIRUS; REVIEW; RNA CLEAVAGE; RNA DEGRADATION; RNA INTERFERENCE; RNA SEQUENCE; TISSUE SPECIFICITY; VIRAL GENE DELIVERY SYSTEM;

GENE THERAPY; GENETIC VECTORS; HIV-1; HUMANS; NEOPLASMS; RNA INTERFERENCE; RNA, SMALL INTERFERING; VIRUS REPLICATION;

EID: 38049103157     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.3.6.655     Document Type: Review

References (49)

1. Lois C, Hong EJ, Pease S, Brown EJ, Baltimore D: Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science 295, 868-872 (2002).
2. Galimi F, Verma IM: Opportunities for the use of lentiviral vectors in human gene therapy. Curr. Top. Microbiol. Immunol. 261, 245-254 (2002).
3. Rubinson DA, Dillon CP, Kwiatkowski AV et al.: A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat. Genet 33(3), 401-406 (2003).
4. Miyagishi M, Sumimoto H, Miyoshi H, Kawakami Y, Taira K: Optimization of an siRNA-expression system with an improved hairpin and its significant suppressive effects in mammalian cells. J. Gene Med. 6, 715-723, (2004).
5. Zamore P, Tushl T, Sharp P, Bartel D: RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 101, 25-33 (2000).
6. Hammond SM, Bernstein E, Beach D, Hannon G: An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 404, 293-296 (2000).
7. Fire A, Xu S, Montogeomery MK, Kostas SA, Driver SE, Mello CC: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391, 806-811 (1998).
8. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494-498 (2001).
9. Ui-Tei K, Naito Y, Takahashi F et al.: Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference. Nucleic Acids Res. 32, 936-948 (2004).
10. Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, Khvorova A: Rational siRNA design for RNA interference. Nature Biotech. 22, 326-330 (2004).
11. Amarzuguioui M, Pryds H: An algorithm for selection of functional siRNA interference. Biochem. Biophys. Res. Commun. 316, 1050-1058 (2004).
12. Brummelkamp, TR, Bernards; R, Agami R: A system for stable expression of short interfering RNAs in mammalian cells. Science 296, 550-553 (2002).
13. Miyagishi M, Taira K: U6 promoter-driven siRNAs with four uridine 3′ overhangs efficiently suppress targeted gene expression in mammalian cells. Nature Biotech. 20, 497-500 (2002).
14. Lee NS, Dohjima T, Bauer G et al.: Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nature Biotech. 20, 500-505 (2002).
15. Paddison PJ, Candy AA, Bernstein E, Hannon GJ, Conklin DS: Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev. 16, 948-958 (2002).
16. Paul CP, Good PD, Winer I, Engelke DR: Effective expression of small interfering RNA in human cells. Nature Biotech. 20, 505-508 (2002)
17. Burmmelkamp TR, Bernards R, Agami R: Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2, 243-247 (2002).
18. Barton GM, Medzhitov R: Retroviral delivery of small interfering RNA into primary cells. Proc. Natl Acad. Sci. USA 99, 14943-14945 (2002).
19. Abbas-Terki T, Blanco-Bose W, Deglon N, Pralong W, Aebischer P: Lentiviral-mediated RNA interference. Human Gene Therapy 13, 2197-2201 (2002).
20. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachian I: Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nature Biotech. 23, 457-462 (2005).
21. Hornung V, Guenthner-Biller M, Bourquin C et al.: Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nature Med. 11, 263-270 (2005).
22. Heil F, Hemmi H, Hochrein H et al.: Species-specific recognition of single-stranded RNA via roll-like receptor 7 and 8. Science 303, 1526-1529 (2004).
23. Yoneyama M, Kikuchi M, Natsukawa T et al.: The RNA helicase RIG-1 has an essential function in double-stranded RNA-induced innate antiviral responses. Nature Immunol. 5, 730-737 (2004).
24. Yoneyama M, Kukuchi M, Matsumoto K et al.: Shared and unique functions of the DExD/H-box helicases; RIG-1, MDA5, and LGP2 in antiviral innate immunity. J. Immunol. 175, 2851-2858 (2005).
25. Marques JT, Devosse T, Wang D et al.: A structural basis for discriminating between self and nonself double-stranded RNAs in mammalian cells. Nature Biotech. 24, 559-565 (2006).
26. Mohamedali A, Moreau-Gaudry F, Richard E, Xia P, Nolta J, Malik P: Self-inactivating lentiviral vectors resist proviral methylation but do not confer position-independent expression in hematopoietic stem cells. Mol. Ther. 10, 249-259 (2004)
27. Jackson AL, Bartz SR, Schelter J et al.: Expression profiling reveals off-target gene regulation by RNAi. Nature Biotech. 21, 635-637 (2003).
28. Grimm D, Streetz KL, Jopling CL et al.: Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441, 537-541 (2006).
29. Miyoshi H, Blömer U, Takahashi M, Gage FH, Verma IM: Development of a self-inactivating lentivirus vector. J. Virol. 72(10), 8150-8157 (1998).
30. Wiznerowicz M, Trono D: Conditional suppression of cellular genes: lentivirus vector-mediated drug-inducible RNA interference. J. Virol. 77, 8957-8961 (2003).
31. Sumimoto H, Hirata K, Yamagata S et al.: Effective inhibition of cell growth and invasion of melanoma by combined suppression of BRAF (V599E) and Skp2 with lentiviral RNAi. Int. J. Cancer 118, 472-476 (2006).
32. Sumimoto H, Imabayashi F, Iwata. T, Kawakami Y: The BRAF-MAPK signaling pathway is essential for cancer immune evasion in human melanoma cells. J. Exp. Med. 203, 1651-1656 (2006).
33. Zennou V, Petit C, Guetard D, Nerhbass U, Montagnier L, Charneau P: Genome nuclear import is mediated by a central DNA flap. Cell 101 (2), 173-185 (2000).
34. Zufferey R, Donello JE, Trono D, Hope TJ: Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J. Virol. 73, 2886-2892 (1999).
35. Breckpot K, Aerts JL, Thielemans K: Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics. Gene Therapy 14, 847-862 (2007).
36. Xia H, Mao Q, Paulson H, Davidson BL: siRNA-mediated gene silencing in vitro and in vivo. Nature Biotech. 20, 1006-1010 (2002).
37. Kasim V, Miyagishi M, Taira K: Control of siRNA expression using the Cre-loxP recombination system. Nucleic Acids Res. 32, E66 (2004).
38. Hitz C, Worst W, Kühn R: Conditional brain-specific knockdown of MAPK using Cre/loxP regulated RNA interference. Nucleic Acids Res. 35, E90 (2007).
39. Coumoul X, Li W, Wang RH, Deng C: Inducible suppression of Fgr2 and Survivin in ES cells using combination of the RNA inteference (RNAi) and the Cre-LoxP sytem. Nucleic Acids Res. 32, E85 (2004).
40. Lili Y, Bailey L, Baltimore D, Wang P: Targeting lentiviral vectors to specific cell types in vivo. Proc. Natl Acad. Sci. USA 103, 11479-11484 (2006).
41. + hematopoietic cells using novel ligand display technology. Blood 104, 2697-2703 (2004).
42. Pai SI, Lin YY, Macaes B, Meneshian A, Hung CF, Wu TC: Prospects of RNA interference therapy for cancer. Gene Therapy, 13, 464-477 (2006).
43. Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA: Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res. 63, 5198-5202 (2003).
44. Sumimoto H, Miyagishi M, Miyoshi H et al.: Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference. Oncogene 23, 6031-6039 (2004).
45. Soutschek J, Akinc A, Bramlage B et al.: Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432, 173-178 (2004).
46. Song E, Zhu P, Lee SK et al.: Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nature Biotech. 23, 709-717 (2005).
47. Medarova Z, Pham W, Farrar C, Petkova V, Moore A. In vivo imaging of siRNA delivery and silencing in tumors. Nature Med. 13, 372-377 (2007).
48. Kumar P, Wu H, McBride JL et al.: Transvascular delivery of small interfering RNA to the central nervous system. Nature 448, 39-43 (2007).
49. Zender L, Hütker S, Liedtke C et al.: Caspase 8 small interfering RNA prevents acute liver failure in mice. Proc. Natl Acad. Sci. USA 100, 7797-7802 (2003).